A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and lenacapavir (BIC/LEN) – may simplify treatment significantly for people with HIV who currently take very complex treatments.